Efficacy and safety of combination therapy with vildagliptin and nateglinide in type 2 diabetes. - combination therapy of vildagliptin and nateglinide

Department of Medicine, Metabolism and Endocrinology, Juntendo University Graduate School of Medicine0 个研究点目标入组 40 人开始时间: 2010年9月30日最近更新: 2023年10月17日

试验速览

暂无简介。

•1) type 1 diabetes 2) patients who has been prescribed sulfonylurea or alpha glucosidase inhibitor 3) patients who have serious liver disease (AST and/or ALT are more than 80IU/L) 4) patients who have serious kidney disease (Serum Cr is more than 1.5mg/dL) 5) patients who have serious heart disease ( patients who have apparent heartfailure or myocardial infarction within 3 months) 6) patients who have serious pancreatic disease 7) patients with cancer 8) anemic patients (Hb is less than 11g/dL) 9) patients with thrombocytepenia (Platelet count is less than 100000/mm3) 10) patients with serious diabetic complications including progressed neutopathy and proliferative retinopathy 11) patietns with serious infection, inflammation, or injuary. pre- or post- operative state 12) patients who have inflammatory bowel disease, ulcer in bowel, ileus and high risk for ileus 13) patinets with chronic bowel diseases which have probability to induce malabsorption syndrome 14) patients who has the disease which is deteriorated with increase of gas in bowel 15) heavy alcohol drinker (patients who drink more than 480mL of Japanese Sake, 2L of beer, 180mL of whisky, 360mL of wine, or 360mL of Shochu per day) 16) patients who are pregnant, hope to be pregnant, or are in lactation period 17) patients who have viral infection (HBV,HCV) 18) patients who are not applicable to this study judged by the medical doctor.

发起方

Department of Medicine, Metabolism and Endocrinology, Juntendo University Graduate School of Medicine